Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells

References

• Barnes J, Anderson L A, Phillipson J D. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583–600
   PubMed Web of Science ®Google Scholar
• Quiney C, Billard C, Faussat A M, Salanoubat C, Ensaf A, Fourneron J D, et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006; 20: 491–497
   PubMed Web of Science ®Google Scholar
• Quiney C, Billard C, Mirshahi P, Fourneron J D, Kolb J P. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 2006; 20: 583–589
   PubMed Web of Science ®Google Scholar
• Medina M A, Martinez-Poveda B, Amores-Sanchez M I, Quesada A R. Hyperforin: more than an antidepressant bioactive compound?. Life Sci 2006; 79: 105–111
   PubMed Web of Science ®Google Scholar
• Quiney C, Billard C, Salanoubat C, Fourneron J D, Kolb J P. Hyperforin, a new lead compound against the progression of cancer and leukemia?. Leukemia 2006; 20: 1519–1525
   PubMed Web of Science ®Google Scholar
• Schempp C M, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer C, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 2002; 21: 1242–1250
   PubMed Web of Science ®Google Scholar
• Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 2003; 56: 121–132
   PubMed Web of Science ®Google Scholar
• Zhou S, Lim L Y, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57–104
   PubMed Web of Science ®Google Scholar
• Pal D, Mitra A K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131–2145
   PubMed Web of Science ®Google Scholar
• Weber C C, Kressmann S, Fricker G, Muller W E. Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry 2004; 37: 292–298
   PubMed Web of Science ®Google Scholar
• Wang E J, Barecki-Roach M, Johnson W W. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004; 56: 123–128
   PubMed Web of Science ®Google Scholar
• Ambudkar S V, Dey S, Hrycyna C A, Ramachandra M, Pastan I, Gottesman M M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–398
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink M M, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 2000; 38: 94–110
   PubMed Web of Science ®Google Scholar
• Marie J P. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001; 13: 463–469
   PubMed Web of Science ®Google Scholar
• Wulf G, Kluding H, Ho A D, Doerner M, Doehner H, Manegold C, et al. Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northern blot analysis. Leuk Res 1994; 18: 475–484
   PubMed Web of Science ®Google Scholar
• Doyle L A, Yang W, Abruzzo L V, Krogmann T, Gao Y, Rishi A K, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665–15670
   PubMed Web of Science ®Google Scholar
• Doyle L A, Ross D D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–7358
   PubMed Web of Science ®Google Scholar
• Zhao H, Dugas N, Mathiot C, Delmer A, Dugas B, Sigaux F, et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92: 1031–1043
   PubMed Web of Science ®Google Scholar
• Harvey W, Srour E F, Turner R, Carey R, Maze R, Starrett B, et al. Characterization of a new cell line (ESKOL) resembling hairy-cell leukemia: a model for oncogene regulation and late B-cell differentiation. Leuk Res 1991; 15: 733–744
   PubMed Web of Science ®Google Scholar
• Kern C, Cornuel J F, Billard C, Tang R, Rouillard D, Steunou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679–688
   PubMed Web of Science ®Google Scholar
• Zhou D C, Marie J P, Maisonneuve L, Faussat-Suberville A M, Zittoun R. Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant hematopoietic HL60/DNR cell line. Exp Hematol 1993; 21: 779–784
   PubMed Web of Science ®Google Scholar
• Fourneron J D, Naït-Si Y. Effect of eluent pH on HPLC/UV analysis of hyperforin. Phytochem Anal 2006; 17: 71–77
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat A M, Sayada L, Perrot J Y, Chaoui D, Marie J P, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004; 10: 7896–7902
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat A M, Sayada L, Perrot J Y, Tang R, Chaoui D, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005; 11: 7764–7772
   PubMed Web of Science ®Google Scholar
• Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, et al. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751–1758
   PubMed Web of Science ®Google Scholar
• Rabindran S K, Ross D D, Doyle L A, Yang W, Greenberger L M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60: 47–50
   PubMed Web of Science ®Google Scholar
• Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 2005; 33: 547–554
   PubMed Web of Science ®Google Scholar
• Beck J, Niethammer D, Gekeler V. High mdr1- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 1994; 86: 135–142
   PubMed Web of Science ®Google Scholar
• Marie J P, Simonin G, Legrand O, Delmer A, Faussat A M, Lewis A D, et al. Glutathione-S-transferases pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 1995; 9: 1742–1747
   PubMed Web of Science ®Google Scholar
• Wall D M, el-Osta S, Tzelepis D, Bertoncello I, Kantharidis P, Chou S T, et al. Expression of mdr1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia. Br J Haematol 1997; 96: 697–707
   PubMed Web of Science ®Google Scholar
• Albermann N, Schmitz-Winnenthal F H, Z'graggen K, Volk C, Hoffmann M M, Haefeli W E, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949–958
   PubMed Web of Science ®Google Scholar
• De Moerloose B, Dhooge C, Philippe J. Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol 1999; 457: 107–118
   PubMed Web of Science ®Google Scholar
• Grulois I, Fardel O, Dreno B, Lamy T, Le Prise P Y, Fauchet R. Multidrug resistance in B-cell chronic lymphocytic leukemia. Acta Haematologica 1995; 94: 78–83
   PubMed Web of Science ®Google Scholar
• Sparrow R L, Hall F J, Siregar H, Van der Weyden M B. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 1993; 17: 941–947
   PubMed Web of Science ®Google Scholar
• Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, et al. The expression of the multi-drug resistance-associated glycoprotein in B-cell chronic lymphocytic leukemia. Br J Haematol 1991; 77: 460–465
   PubMed Web of Science ®Google Scholar
• Svoboda-Beusan I, Kusec R, Bendelja K, Tudoric-Ghemo I, Jaksic B, Pejsa V, et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000; 85: 1261–1267
   PubMed Web of Science ®Google Scholar
• Reichle A, Diddens H, Altmayr F, Rastetter J, Andreesen R. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type. Cancer Chemotherap Pharmacol 1994; 34: 307–316
   PubMed Web of Science ®Google Scholar
• Burger H, Nooter K, Sonneveld P, Van Wingerden K E, Zaman G J, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 1994; 88: 348–356
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Niewiarowski W, Krykowski E, Robak T, Warzocha K. Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 153–158
   PubMed Web of Science ®Google Scholar
• Raaijmakers M H, de Grouw E P, Heuver L H, van der Reijden B A, Jansen J H, Scheffer G, et al. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res 2005; 29: 1455–1458
   PubMed Web of Science ®Google Scholar
• Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 2004; 27: 773–797
   PubMed Web of Science ®Google Scholar
• Mai I, Bauer S, Perloff E S, Johne A, Uehleke B, Frank B, et al. Hyperforin content determines the magnitude of the St John's wort – cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330–340
   PubMed Web of Science ®Google Scholar
• Mueller S C, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski R G, Miekisch W, et al. The extent of induction of CYP3A by St John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2005; 10: 1–8
   Google Scholar
• Moore L B, Goodwin B, Jones S A, Wisely G B, Serabjit-Singh C J, Willson T M, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500–7502
   PubMed Web of Science ®Google Scholar
• Dona M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004; 64: 6225–6232
   PubMed Web of Science ®Google Scholar
• Gartner M, Muller T, Simon J C, Giannis A, Sleeman J P. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. ChemBioChem 2005; 6: 171–177
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Smolewski P, Cebula B, Szmigielska-Kaplon A, Darzynkiewicz Z, Robak T. Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia. Neoplasma 2004; 51: 181–187
   PubMed Web of Science ®Google Scholar